公开(公告)号：US12129289B2

公开(公告)日：2024-10-29

申请号：US17399205

申请日：2021-08-11

Applicant: H. Lundbeck A/S

Inventor： Jan Torleif Pedersen ,  Kristian Kjaergaard ,  Lars Østergaard Pedersen ,  Ayodeji Abdur-Rasheed Asuni ,  Nina Helen Rosenqvist ,  Justus Claus Alfred Daechsel ,  Karsten Juhl ,  Lena Tagmose ,  Mauro Marigo ,  Thomas Jensen ,  Søren Christensen ,  Laurent David ,  Christiane Volbracht ,  Lone Helboe

IPC: C07K16/18 ,  A61K39/395 ,  A61K49/00 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K39/395 ,  A61K49/00 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N2800/2814 ,  G01N2800/2821

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

公开(公告)号：US12122849B2

公开(公告)日：2024-10-22

申请号：US18157756

申请日：2023-01-20

Applicant: SYSMEX CORPORATION

Inventor： Shingo Maeta ,  Atsushi Fukunaga ,  Reema Bajaj

IPC: C07K16/00 ,  C07K16/26 ,  C07K16/32 ,  C07K16/40 ,  G16B15/20 ,  G16B20/30

CPC classification number: C07K16/40 ,  C07K16/00 ,  C07K16/26 ,  C07K16/32 ,  G16B15/20 ,  G16B20/30 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92

Abstract: Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 5th, 9th and 22nd amino acid residues of a light chain defined by Kabat method to charged amino acid residues.

公开(公告)号：US20240343814A1

公开(公告)日：2024-10-17

申请号：US18760575

申请日：2024-07-01

Applicant: Viridian Therapeutics, Inc.

Inventor： Vahe BEDIAN ,  Yang ZHAO

IPC: C07K16/28 ,  A61K31/7088 ,  A61K35/12 ,  A61P27/02 ,  C07K16/46

CPC classification number: C07K16/2863 ,  A61K31/7088 ,  A61K35/12 ,  A61P27/02 ,  C07K16/461 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/94

Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.

公开(公告)号：US12116409B2

公开(公告)日：2024-10-15

申请号：US17408113

申请日：2021-08-20

Applicant: Redwood Bioscience, Inc.

Inventor： David Rabuka ,  Robert George Edward Holgate ,  Francis Joseph Carr

IPC: C07K16/00 ,  A61K39/395 ,  A61K39/40 ,  C07K16/28 ,  C07K17/02 ,  C07K17/08 ,  C07K17/10 ,  C12N9/16 ,  C12P21/08

CPC classification number: C07K16/2803 ,  C07K16/2851 ,  C07K17/02 ,  C07K17/08 ,  C07K17/10 ,  C12N9/16 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C12Y301/06

Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.

公开(公告)号：US12110332B2

公开(公告)日：2024-10-08

申请号：US16765008

申请日：2017-11-20

Applicant: Taizhou Mabtech Pharmaceutical Co., Ltd.

Inventor： Yajun Guo

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P37/02 ,  C07K14/705

CPC classification number: C07K16/2827 ,  A61P35/00 ,  A61P37/02 ,  C07K14/70503 ,  C07K16/2896 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2319/70

Abstract: A bifunctional fusion protein targeting CD47 and PD-L1, which belongs to the field of biomedicine and solves the problems that anti-PD-1/PD-L1 treatment has poor effect on low immunogenic tumors and anti-CD47 treatment has poor targeting properties. The fusion protein consists of a CD47-binding moiety and a PD-L1-binding moiety linked by means of a disulfide bond, can block both the binding of CD47 to SIRPa and the binding of PD-L1 to PD-1, not only activating macrophage phagocytosis of tumor cells and promoting antigen presentation in innate immunity, but also promoting tumor-specific T cell activation in acquired immunity, and has lower hematological toxicity. The fusion protein has better anti-tumor efficacy and hematological safety than anti-PD-L1 or anti-CD47 therapy alone, and animals from which a tumor has disappeared after the treatment of the fusion protein produce immunity against re-inoculation of the same tumor cell.

公开(公告)号：US20240327785A1

公开(公告)日：2024-10-03

申请号：US18543857

申请日：2023-12-18

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn Macdonald ,  Sean Stevens ,  Cagan Gurer ,  Andrew J. Murphy ,  Karolina A. Meagher

IPC: C12N5/0735 ,  A01K67/0275 ,  A01K67/0278 ,  C07K16/00 ,  C07K16/18 ,  C07K16/46 ,  C12N15/10 ,  C12N15/85

CPC classification number: C12N5/0606 ,  A01K67/0275 ,  A01K67/0278 ,  C07K16/00 ,  C07K16/18 ,  C07K16/461 ,  C07K16/462 ,  C12N15/10 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/02 ,  A01K2267/0381 ,  C07K2317/10 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/50 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/64

Abstract: Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.

公开(公告)号：US20240327532A1

公开(公告)日：2024-10-03

申请号：US18645261

申请日：2024-04-24

Applicant: PROMETHEUS BIOSCIENCES, INC. ,  CEDARS-SINAI MEDICAL CENTER

Inventor： Jeffry D. Watkins ,  Cindy T. Dickerson ,  Rafael Rojas ,  Matthew Reissman ,  Patricia McNeeley ,  Janine Bilsborough ,  Bradley Henkle ,  Stephan R. Targan

IPC: C07K16/28 ,  A61P1/04 ,  C07K16/24

CPC classification number: C07K16/2875 ,  A61P1/04 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/76

Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).

公开(公告)号：US12103962B2

公开(公告)日：2024-10-01

申请号：US15117360

申请日：2014-12-19

Applicant: Janssen Pharmaceuticals, Inc.

Inventor： Eszter Nagy ,  Gábor Nagy ,  Valéria Szijárto ,  Luis Guachalla ,  Maximiliano Vasquez

IPC: C07K16/12 ,  A61K39/00 ,  G01N33/569 ,  G01N33/92

CPC classification number: C07K16/1232 ,  G01N33/56916 ,  G01N33/92 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/245 ,  G01N2400/50

Abstract: The invention refers to an isolated antibody that specifically binds to O25b antigen of E. coli strains comprising at least an antibody heavy chain variable region (VH), which comprises any of the CDR1 to CDR3 sequences as listed in FIG. 1, and optionally further comprising an antibody light chain variable region (VL), which comprises any of the CDR4 to CDR6 sequences as listed in FIG. 1, or functionally active CDR variants of any of the forgoing CDR 1-6 sequences.

公开(公告)号：US20240317891A1

公开(公告)日：2024-09-26

申请号：US18734434

申请日：2024-06-05

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Koichiro Yoneyama

IPC: C07K16/36 ,  A61K39/00 ,  A61K39/395 ,  C07K16/46

CPC classification number: C07K16/36 ,  A61K39/395 ,  C07K16/46 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515

Abstract: The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.

公开(公告)号：US12098191B2

公开(公告)日：2024-09-24

申请号：US17673449

申请日：2022-02-16

Applicant: MedImmune Limited

Inventor： Maria Groves ,  Suzanne Gustavsson ,  Kina Höglund ,  Chris Lloyd ,  Adrian Nickson ,  Camilla Niva ,  Sylvia Simon ,  David Lowne ,  Fraser Welsh ,  Per-Ola Freskgard

IPC: C07K16/18 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61P25/28

CPC classification number: C07K16/18 ,  A61P25/28 ,  A61K38/1716 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/92

Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.